Shopping Cart
- Remove All
- Your shopping cart is currently empty
Camidanlumab tesirine (ADCT 301) is an ADC consisting of a human IgG1 antibody, HuMax-TAC, targeting CD25, which is conjugated through a dipeptide-cleavable linker to pyrrolobenzodiazepine (PBD) dimer payloads. The drug-antibody ratio (DAR) of Camidanlumab tesirine is 2.3. It binds to human CD25 with picomolar affinity and exhibits potent and selective cytotoxicity against human lymphoma cell lines expressing CD25.
Pack Size | Price | Availability | Quantity |
---|---|---|---|
1 mg | Inquiry | Backorder | |
5 mg | Inquiry | Backorder |
Description | Camidanlumab tesirine (ADCT 301) is an ADC consisting of a human IgG1 antibody, HuMax-TAC, targeting CD25, which is conjugated through a dipeptide-cleavable linker to pyrrolobenzodiazepine (PBD) dimer payloads. The drug-antibody ratio (DAR) of Camidanlumab tesirine is 2.3. It binds to human CD25 with picomolar affinity and exhibits potent and selective cytotoxicity against human lymphoma cell lines expressing CD25. |
In vitro | Camidanlumab tesirine (ADCT 301; 3, 10 ng/mL; 48 h) causes dose-dependent G2-M phase arrest, peaking at 48 hours. It (10 ng/mL; 24-96 h) induces apoptosis. The compound exhibits a GI50 range of 0.04-2.94 ng/mL in CD25 positive cell lines, but >1,000 ng/mL in CD25 negative cell lines. In both antigen-expressing and non-expressing cell lines, for the unconjugated ADC, the GI50 value is >1,000 ng/mL. |
In vivo | Camidanlumab tesirine (ADCT 301; 0.1-0.6 mg/kg/day;Intravenous injection; 60 days) inhibits tumor growth in a dose-dependent manner. Its half-life, calculated through analysis of the bound antibody with a DAR component ≥1, is 7.3 days. |
Synonyms | ADCT 301 |
Cas No. | 1853239-04-9 |
Storage | store at low temperature | store at -20°C | Shipping with blue ice/Shipping at ambient temperature. |
Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.